Tandem Diabetes Care (TNDM) Liabilities and Shareholders Equity (2013 - 2026)

Tandem Diabetes Care (TNDM) has reported Liabilities and Shareholders Equity for 14 consecutive years, with $1.2 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Liabilities and Shareholders Equity rose 31.8% year-over-year to $1.2 billion; the trailing twelve-month figure through Jun 2026 stood at $4.1 billion (up 9.13% YoY), and the FY2025 full-year result was $881.1 million, down 8.94% from the prior year.
• Liabilities and Shareholders Equity steadied at $1.2 billion in Q2 2026 per TNDM's latest filing, from $1.2 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $1.2 billion in Q2 2026 and bottomed at $874.7 million in Q3 2025.
• Historically, Liabilities and Shareholders Equity has averaged $978.4 million across 5 years, with a median of $953.4 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity surged 34.6% in 2022, then decreased 10.27% in 2023.
• Over 5 years, Liabilities and Shareholders Equity stood at $1.1 billion in 2022, then fell by 9.51% to $952.7 million in 2023, then rose by 1.57% to $967.7 million in 2024, then decreased by 8.94% to $881.1 million in 2025, then soared by 30.99% to $1.2 billion in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $1.2 billion, $1.2 billion, and $881.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.